# Efficacy and Safety of Saxagliptin VS. Glimepiride in Chinese T2DM Patients Controlled Inadequately With Metformin

Study · id `cardio:ct-nct02280486` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02280486](<https://clinicaltrials.gov/study/NCT02280486>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02280486

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 388 participants.

## Technical summary

Registry record NCT02280486. Randomized; no masking; primary purpose treatment. Start 2015-01 (registry gives no type); primary completion 2016-10 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 388 participants (enrolled count; ClinicalTrials.gov record NCT02280486, source copy `cardio:ctgov-nct02280486-2018-07-23`, retrieved 2026-10-26)
- Start date: 2015-01 (registry gives no type) (ClinicalTrials.gov record NCT02280486, source copy `cardio:ctgov-nct02280486-2018-07-23`, retrieved 2026-10-26)
- Primary completion: 2016-10 (actual) (ClinicalTrials.gov record NCT02280486, source copy `cardio:ctgov-nct02280486-2018-07-23`, retrieved 2026-10-26)
- Completion: 2017-10 (actual) (ClinicalTrials.gov record NCT02280486, source copy `cardio:ctgov-nct02280486-2018-07-23`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT02280486, source copy `cardio:ctgov-nct02280486-2018-07-23`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02280486-2018-07-23`, retrieved 2026-10-26)

## The registry's words

- Brief title: Efficacy and Safety of Saxagliptin VS. Glimepiride in Chinese T2DM Patients Controlled Inadequately With Metformin
- Acronym: SPECIFY
- Condition: Type 2 Diabetes
- Intervention (Drug): Saxagliptin
- Intervention (Drug): Glimepiride
- Lead sponsor: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
- Lead sponsor class: OTHER
- Collaborator: The First Affiliated Hospital with Nanjing Medical University
- Collaborator class: OTHER
- Collaborator: Zhongda Hospital
- Collaborator class: OTHER
- Collaborator: Nanjing PLA General Hospital
- Collaborator class: OTHER
- Collaborator: Changzhou No.2 People's Hospital
- Collaborator class: OTHER
- Collaborator: The First Affiliated Hospital of Soochow University
- Collaborator class: OTHER
- Collaborator: Wuxi People's Hospital
- Collaborator class: OTHER
- Collaborator: The First Affiliated Hospital of Anhui Medical University
- Collaborator class: OTHER
- Collaborator: Huai'an First People's Hospital
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School (`cardio:org-the-affiliated-nanjing-drum-tower-hospital-of-nanjing-3a906f`)
- Registry lists this organization as a collaborator: The First Affiliated Hospital with Nanjing Medical University (`cardio:org-the-first-affiliated-hospital-with-nanjing-medical-898271`)
- Registry lists this organization as a collaborator: Zhongda Hospital (`cardio:org-zhongda-hospital`)
- Registry lists this organization as a collaborator: The First Affiliated Hospital of Soochow University (`cardio:org-the-first-affiliated-hospital-of-soochow-university`)
- Registry lists this organization as a collaborator: The First Affiliated Hospital of Anhui Medical University (`cardio:org-the-first-affiliated-hospital-of-anhui-medical-university`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Comparative effect of saxagliptin and glimepiride with a composite endpoint of adequate glycaemic control without hypoglycaemia and without weight gain in patients uncontrolled with metformin therapy: Results from the SPECIFY study, a 48-week, multi-centre, randomized, controlled trial (`cardio:pubmed-30520221`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: a5dab4d4650efba12642d054764b41463fe8ac57ec18c9931167d6fe11d0115d
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
